Factor V Leiden: Should we screen oral contraceptive users and pregnant women?

BMJ

Volumn 313, Issue 7065, 1996, Pages 1127-

  Vandenbroucke, Jan p ^a   Van Der Meer, Felix J M ^a   Helmerhorst, Frans m ^a   Rosendaal, Frits R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT;

ANTICOAGULATION; BLEEDING; DEEP VEIN THROMBOSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; LUNG EMBOLISM; ORAL CONTRACEPTION; PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; PUERPERAL DISORDER; SCREENING; SHORT SURVEY;

ACCEPTORS--WOMEN; BIOLOGY; CONTRACEPTION; CONTRACEPTIVE METHODS--CONTRAINDICATIONS; CRITIQUE; DEMOGRAPHIC FACTORS; DEVELOPED COUNTRIES; DISEASES; EMBOLISM; ENGLAND; EUROPE; EVALUATION; EXAMINATIONS AND DIAGNOSES; FAMILY PLANNING; FAMILY PLANNING PROGRAMS; GENETICS; NORTHERN EUROPE; ORAL CONTRACEPTIVES--CONTRAINDICATIONS; POPULATION; POPULATION CHARACTERISTICS; PREGNANT WOMEN; RISK ASSESSMENT; SCREENING; THROMBOEMBOLISM; THROMBOSIS--PREVENTION AND CONTROL; UNITED KINGDOM; VASCULAR DISEASES;

CONTRACEPTIVES, ORAL; FACTOR V; FEMALE; GENETIC SCREENING; HEALTH EDUCATION; HUMANS; MASS SCREENING; MUTATION; PEDIGREE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREVALENCE; PUERPERAL DISORDERS; RISK ASSESSMENT; RISK FACTORS; THROMBOPHLEBITIS;

EID: 0029853469     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.313.7065.1127     Document Type: Article

References (34)

1. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1454–7.
2. Bloemenkamp KWM, Rosendaal F, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995; 346: 1593–5.
3. Pasi KJ, Perry DJ, Lee CA. Thromboembolism and the combined oral contraceptive pill. Lancet 1995; 345: 1437.
4. Machin SJ, Mackie IJ, Guillebaud J. Factor V Leiden mutation, venous thromboembolism and combined oral contraceptive usage. Br J Fam Plann 1995; 21: 13–4.
5. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210–3.
6. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133–4.
7. Bridey F, Wolff M, Laissy JP, Morin V, Lefebvre M, de Prost D. Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost 1995; 74: 1582.
8. Dahlback B. Are we ready for factor V Leiden screening? Lancet 1996; 347: 1346–7.
9. Dahlback B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene and venous thrombosis. Thromb Haemost 1995; 73: 739–42.
10. Dahlback B. Physiologic anticoagulation: inherited resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923–7.
11. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93.
12. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582–8.
13. Anderson FA, Wheeler B, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep venous thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933–8.
14. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7.
15. Ridker PM, Hennekens Ch H, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912–7.
16. Centraal Bureau voor de Statistiek. Gebruik van anticonceptiepil door vrouwen van 16 tot 49 jaar naar leeftijd (1994). Statistisch Jaarboek 1996. 's-Gravenhage: Centraal Bureau voor de Statistiek, 1996: 502.
17. Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thrombosis: a quantitative discussion of the uncertainties. J Intern Med 1995; 238: 31–7.
18. Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996; 75: 524–5.
19. Carter CJ. The natural history and epidemiology of venous thrombosis. Progress in Cardiovascular Diseases 1994; 36: 423–8.
20. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpainter K, Hennekens CH. Factor V Leiden and risk of recurrent idiopathic venous thrombosis. Circulation 1995; 92: 2800–2.
21. Badaracco MA, Vessey MP. Recurrence of venous thromboembolic disease and use of oral contraceptives. BMJ 1974; i: 215–7.
22. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (APC-resistance). Blood 1995; 85: 1504–8.
23. Briet E, Meer van der FJM, Rosendaal FR, Houwing-Duistermaat JJ, van Houwelingen JC. The family history and inherited thrombophilia. Br J Haematol 1994; 87: 348–52.
24. Majerus PW. Bad blood by mutation. Nature 1994; 369: 14–5.
25. Treffers PE, Huidekoper BJ, Weenink GH, Kloosterman. Epidemiological observations of thromboembolic disease during pregnancy and in the puerperium in 56,022 women. Int J Gynecol Obstet 1983; 21: 327–1.
26. Bonnar J. Epidemiology of venous thromboembolism in pregnancy and the puerperium. In: Greer IA, Turpie AGG, Forbes CD, eds. Haemostasis and thrombosis in obstetrics and gynaecology. London: Chapman and Hall Medical, 1992: 257–66.
27. Sachs BP, Brown DA, Driscoll SG, Schulman E, Acker D, Ransil BJ, et al. Maternal mortality in Massachusetts. New Engl J Med 1987; 316: 667–72.
28. Meer van der FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153: 1557–62.
29. Fihn SD. Aiming for safe anticoagulation. New Engl J Med 1995; 333; 54–5.
30. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271: 1780–5.
31. Tengborn L, Bergqvist D, Matzsch Th, Bergqvist A, Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Is there need for thromboprophylaxis? Am J Obstet Gynecol 1989; 160: 90–4.
32. Toglia MR, Weg JG. Current concepts: venous thromboembolism during pregnancy. N Engl J Med 1996; 335: 108–14.
33. Dahlback B. Factor V gene mutation causing inherited resistance of activated protein C as a basis for venous thromboembolism. J Intern Med 1995; 237: 221–7.
34. Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittmannn E, Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost 1994; 71: 441–5.